Generation of cell hybrids via a fusogenic cell line

Cheong, Siew Chiat; Blangenois, Isabelle; Franssen, Jean-Denis; Servais, Charlotte; Phan, Vy; Trakatelli, M.; Bruyns, Catherine; Vile, Richard G.; Velu, Thierry; Brandenburger, Anne-Nicole

doi:10.1002/jgm.906

Cited by 9 publications

(5 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DC-tumor cell hybrids can be created by exposing DCs and tumor cells in polythelene glycol (72). Tumor cells can also be transfected with a viral fusogenic membrane glycoprotein and pelleted with DCs to achieve a DCtumor hybrid (73). Besides, electrofusion technique has been applied in this strategy (74).…”

Section: Dc-tumor Cell Fusion Vaccinementioning

confidence: 99%

Breast Cancer Vaccines: Disappointing or Promising?

Zhu

2022

Front. Immunol.

View full text Add to dashboard Cite

Breast cancer has become the most commonly diagnosed cancer globally. The relapse and metastasis of breast cancer remain a great challenge despite advances in chemotherapy, endocrine therapy, and HER2 targeted therapy in the past decades. Innovative therapeutic strategies are still critically in need. Cancer vaccine is an attractive option as it aims to induce a durable immunologic response to eradicate tumor cells. Different types of breast cancer vaccines have been evaluated in clinical trials, but none has led to significant benefits. Despite the disappointing results at present, new promise from the latest study indicates the possibility of applying vaccines in combination with anti-HER2 monoclonal antibodies or immune checkpoint blockade. This review summarizes the principles and mechanisms underlying breast cancer vaccines, recapitulates the type and administration routes of vaccine, reviews the current results of relevant clinical trials, and addresses the potential reasons for the setbacks and future directions to explore.

show abstract

Section: Dc-tumor Cell Fusion Vaccinementioning

confidence: 99%

Breast Cancer Vaccines: Disappointing or Promising?

Zhu

2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The efficacy of antitumor immunity induced by DC/tumor fusion vaccines has been demonstrated in murine models using melanoma [24–32], colorectal [17, 30, 31, 33–41], breast [42–47], esophageal [48], pancreatic [49, 50], hepatocellular [51–55], lung [22, 41, 56–59], renal cell [60] carcinoma, sarcoma [61–66], myeloma [67–74], mastocytoma [75], lymphoma [76], and neuroblastoma [77]. The fusion cells generated with human DC and tumor cell also have the ability to present multiple tumor antigens, thus increasing the frequency of responding T cells and maximizing antitumor immunity capable of killing tumor targets such as colon [78–84], gastric [85, 86], pancreatic [87], breast [47, 88–93], laryngeal [94], ovarian [95–97], lung [85, 98], prostate [99, 100], renal cell [101, 102], hepatocellular [103–105] carcinoma, leukemia [106–111], myeloma [112, 113], sarcoma [114, 115], melanoma [116–119], glioma [120], and plasmacytoma [121]. …”

Section: Dc/tumor Fusion Vaccinesmentioning

confidence: 99%

Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines

Koido

Homma

Takahara

et al. 2011

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

Although dendritic cell (DC)- based cancer vaccines induce effective antitumor activities in murine models, only limited therapeutic results have been obtained in clinical trials. As cancer vaccines induce antitumor activities by eliciting or modifying immune responses in patients with cancer, the Response Evaluation Criteria in Solid Tumors (RECIST) and WHO criteria, designed to detect early effects of cytotoxic chemotherapy in solid tumors, may not provide a complete assessment of cancer vaccines. The problem may, in part, be resolved by carrying out immunologic cellular monitoring, which is one prerequisite for rational development of cancer vaccines. In this review, we will discuss immunologic monitoring of cellular responses for the evaluation of cancer vaccines including fusions of DC and whole tumor cell.

show abstract

“…More importantly, in preclinical studies the fusions were also effective to induce CTL responses in vitro using colorectal [25, 97–102], gastric [103, 104], pancreatic [105], breast [43, 106–110], laryngeal [111], ovarian [34, 44, 112], lung [113], prostate [114, 115], renal [116, 117], and hepatocellular [118–120] carcinoma, leukemia [121–126], myeloma [127, 128] sarcoma [129, 130], melanoma [29, 131–133], glioma [124], and plasmacytoma [134]. …”

Section: Tumor/dc Fusions Vaccinementioning

confidence: 99%

Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions

Koido

Homma

Hara

et al. 2010

Clinical and Developmental Immunology

View full text Add to dashboard Cite

The goal of cancer vaccines is to induce antitumor immunity that ultimately will reduce tumor burden in tumor environment. Several strategies involving dendritic cells- (DCs)- based vaccine incorporating different tumor-associated antigens to induce antitumor immune responses against tumors have been tested in clinical trials worldwide. Although DCs-based vaccine such as fusions of whole tumor cells and DCs has been proven to be clinically safe and is efficient to enhance antitumor immune responses for inducing effective immune response and for breaking T-cell tolerance to tumor-associated antigens (TAAs), only a limited success has occurred in clinical trials. This paper reviews tumor immune escape and current strategies employed in the field of tumor/DC fusions vaccine aimed at enhancing activation of TAAs-specific cytotoxic T cells in tumor microenvironment.

show abstract

Generation of cell hybrids via a fusogenic cell line

Abstract: It is speculated that this tri-parental hybrid approach offers new possibilities to further modulate the anti-tumour effect of the DC/TC hybrids since it allows the expression of relevant immunostimulatory molecules by appropriate engineering of the fusogenic cell line.

Cited by 9 publications

References 60 publications

Breast Cancer Vaccines: Disappointing or Promising?

Breast Cancer Vaccines: Disappointing or Promising?

Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines

Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions

Contact Info

Product

Resources

About